Synmosa Biopharma (TWO:4114) — Market Cap & Net Worth
Market Cap & Net Worth: Synmosa Biopharma (4114)
Synmosa Biopharma (TWO:4114) has a market capitalization of $488.27 Million (NT$15.50 Billion) as of May 3, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #12656 globally and #451 in its home market, demonstrating a -2.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synmosa Biopharma's stock price NT$30.80 by its total outstanding shares 503175635 (503.18 Million). Analyse 4114 cash generation efficiency to see how efficiently the company converts income to cash.
Synmosa Biopharma Market Cap History: 2015 to 2026
Synmosa Biopharma's market capitalization history from 2015 to 2026. Data shows growth from $214.96 Million to $488.27 Million (9.22% CAGR).
Synmosa Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synmosa Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Synmosa Biopharma's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.62x
Synmosa Biopharma's market cap is 0.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $198.07 Million | $1.87 Billion | $166.65 Million | 0.11x | 1.19x |
| 2017 | $191.94 Million | $1.86 Billion | $4.69 Million | 0.10x | 40.94x |
| 2018 | $225.39 Million | $2.36 Billion | $430.90 Million | 0.10x | 0.52x |
| 2019 | $223.39 Million | $2.68 Billion | $47.09 Million | 0.08x | 4.74x |
| 2020 | $253.53 Million | $3.04 Billion | $638.11 Million | 0.08x | 0.40x |
| 2021 | $266.55 Million | $3.23 Billion | $303.86 Million | 0.08x | 0.88x |
| 2022 | $616.51 Million | $4.39 Billion | $799.09 Million | 0.14x | 0.77x |
| 2023 | $547.10 Million | $5.14 Billion | $594.83 Million | 0.11x | 0.92x |
| 2024 | $546.92 Million | $5.55 Billion | $684.68 Million | 0.10x | 0.80x |
| 2025 | $513.63 Million | $6.19 Billion | $821.85 Million | 0.08x | 0.62x |
Competitor Companies of 4114 by Market Capitalization
Companies near Synmosa Biopharma in the global market cap rankings as of May 3, 2026.
Key companies related to Synmosa Biopharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Synmosa Biopharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Synmosa Biopharma's market cap moved from $214.96 Million to $ 488.27 Million, with a yearly change of 9.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$488.27 Million | -4.94% |
| 2025 | NT$513.63 Million | -6.09% |
| 2024 | NT$546.92 Million | -0.03% |
| 2023 | NT$547.10 Million | -11.26% |
| 2022 | NT$616.51 Million | +131.29% |
| 2021 | NT$266.55 Million | +5.13% |
| 2020 | NT$253.53 Million | +13.49% |
| 2019 | NT$223.39 Million | -0.89% |
| 2018 | NT$225.39 Million | +17.43% |
| 2017 | NT$191.94 Million | -3.09% |
| 2016 | NT$198.07 Million | -7.86% |
| 2015 | NT$214.96 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Synmosa Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $488.27 Million USD |
| MoneyControl | $488.27 Million USD |
| MarketWatch | $488.27 Million USD |
| marketcap.company | $488.27 Million USD |
| Reuters | $488.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more